IK

Ikena Oncology IncNASDAQ IKNA Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.082

Micro

Exchange

XNAS - Nasdaq

IKNA Stock Analysis

IK

Uncovered

Ikena Oncology Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

1/100

Low score

Market cap $B

0.082

Dividend yield

Shares outstanding

36.258 B

Ikena Oncology, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 80 full-time employees. The company went IPO on 2021-03-26. The firm lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. The company is also combining IK-930 with other targeted therapies across several indications, including EGFR mutated non-small cell lung cancer and KRAS mutated cancers. The firm has initiated a first in human Phase I clinical trial of IK-930 in patients with advanced solid tumors with a high frequency of Hippo pathway alternations. Its clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment. IK-175 is an oral inhibitor of aryl hydrocarbon receptor, which it is evaluating in a Phase Ia/Ib clinical trial in solid tumors and in urothelial carcinomas as monotherapy and in combination with nivolumab.

View Section: Eyestock Rating